{"id":926760,"date":"2026-01-13T08:57:58","date_gmt":"2026-01-13T13:57:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/"},"modified":"2026-01-13T08:57:58","modified_gmt":"2026-01-13T13:57:58","slug":"evaxion-expands-ai-immunology-platform-into-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/","title":{"rendered":"Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <b>Evaxion adds autoimmune disease as a third disease area as it expands its therapeutic focus<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>In future, Evaxion\u2019s proprietary AI-Immunology\u2122 platform will enable the discovery and development of drug candidates targeting cancer, infectious and autoimmune diseases, leveraging its unique scalability<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>Autoimmune diseases represent a high unmet medical need and offer significant partnership potential across all stages of drug development<\/b>\n        <\/li>\n<li style=\"text-align:justify\">\n          <b>Evaxion also announces additional 2026 company milestones and maintains cash runway into second half of 2027<\/b>\n        <\/li>\n<\/ul>\n<p align=\"justify\">COPENHAGEN, Denmark, January 13, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, will expand the use of its proprietary AI-Immunology\u2122 platform to also discover and develop new treatments for autoimmune diseases. Thus, Evaxion will in the future work within cancers, infectious and autoimmune diseases as its core disease areas.<\/p>\n<p align=\"justify\">The expansion leverages the unique scalability of AI-Immunology\u2122 and will increase the pool of diseases for which we can decode the immune system and potentially discover and develop new treatments. In turn, this will improve the quantity and quality of new programs within our pipeline, potentially available for partnership. Autoimmune diseases are characterized by high unmet medical need and offer significant partnership potential across all stages of drug development.<\/p>\n<p align=\"justify\">\u201cAutoimmune diseases can be severely debilitating and even lethal, placing a substantial burden on patients, their families and on society across all stages of life. With AI-Immunology\u2122 we have a unique technology and a platform that we know can deliver new treatment opportunities. By expanding the platform into autoimmune diseases, we have the potential to meaningfully improve the outcome for patients and unlock significant partnership value from the platform,\u201d says Helen Tayton-Martin, CEO at Evaxion.<\/p>\n<p align=\"justify\">We plan to expand and train AI-Immunology\u2122 to be applicable to autoimmune diseases during the second half of 2026. Specifically, the AI-Immunology\u2122 platform potentially allows for development of precision treatments targeting underlying disease mechanisms, in contrast to current treatment approaches that primarily address symptoms. The related work on the autoimmune disease application development is already included in Evaxion\u2019s cashflow outlook and does not impact our cash runway, which still extends to the second half of 2027.<\/p>\n<p align=\"justify\">\n        <b>2026 company milestones<\/b><br \/>\n        <br \/>The expansion to autoimmune diseases represents a new strategic milestone for Evaxion in addition to other milestones for 2026 as outlined below. These reflect continued execution of our strategy of creating value from both our platform and pipeline assets through partnerships.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Milestone<\/b>\n          <\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <b>Target <\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <b>EVX-01<\/b>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Additional biomarker and immunogenicity data<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H1<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <b>AI-Immunology\u2122<\/b>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">New application for autoimmune diseases<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <b>EVX-01<\/b>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Three-year phase 2 clinical efficacy data<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <b>EVX-04 <\/b>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Regulatory filing for phase 1 trial<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <b>EVX-B4 <\/b>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Design and preclinical validation of antigens<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H2<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        \n      <\/p>\n<p align=\"justify\">\n        <b>Contact information<\/b>\u00a0<br \/>Evaxion A\/S<br \/>Mads Kronborg<br \/>Vice President, Investor Relations &amp; Communication<br \/>+45 53 54 82 96 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ciwShSVbErcSu3LBtdZOaEhQVYJOjUuWUbYGFM0tU46KO723GzMAqXF66961ISkRUwlo_U4kZ2iwhQ6s-zYj9A==\" rel=\"nofollow\" target=\"_blank\">mak@evaxion.ai<\/a><\/p>\n<p align=\"justify\">\n        <b>About Evaxion<\/b><br \/>\n        <br \/>Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology\u2122. Evaxion\u2019s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology\u2122, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients\u2019 lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology\u2122 platform and vaccine pipeline, please <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M1qakmDesVI0JBkGhnPZm8uRjFjVKleBf8BaL7zWQBHe0GBPe-qZwmv9KN-5NVeO_GCE6EJckWeTCwa9Nwadnp71QHa-wggRVK_RhmKWghM=\" rel=\"nofollow\" target=\"_blank\">visit our website<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward-looking statement<\/b>\u00a0<br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from other significant geopolitical and macro-economic events;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the US Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3kh1lSFczZIT1IaZoUyRxvA-AAAXdML5jS03nGL4pJFF6I9gZdS1fo2DBRKDo6ypoSFYqOsbKpdzKoQ1VuFZMLzpHaJfY-Dj7_ZdnhSstNE16uSK0QUYdhZUJ7X-JnZhwaDMccutAHeFzDiMXkcdpaSYGYDnBH34Oqm5tf4hUEpnfTgJVIy2aDaR_Rz3wEQ-ps9XHBtCksIK8aEpYh0l6stVk5c2_5FKFs2ZnqHVheE=\" rel=\"nofollow\" target=\"_blank\"><b>www.sec.gov<\/b><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE1OTA0MSM0MDIzMTU2NzgjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MDZmYmM3OTQtZmU4MS00OGY2LWExMzUtZjU0YjEwMmJhNDJlLTEyNjM2NDAtMjAyNi0wMS0xMy1lbg==\/tiny\/Evaxion.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Evaxion adds autoimmune disease as a third disease area as it expands its therapeutic focus In future, Evaxion\u2019s proprietary AI-Immunology\u2122 platform will enable the discovery and development of drug candidates targeting cancer, infectious and autoimmune diseases, leveraging its unique scalability Autoimmune diseases represent a high unmet medical need and offer significant partnership potential across all stages of drug development Evaxion also announces additional 2026 company milestones and maintains cash runway into second half of 2027 COPENHAGEN, Denmark, January 13, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, will expand the use of its proprietary AI-Immunology\u2122 platform to also discover and develop new treatments for autoimmune diseases. Thus, Evaxion will in the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-926760","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Evaxion adds autoimmune disease as a third disease area as it expands its therapeutic focus In future, Evaxion\u2019s proprietary AI-Immunology\u2122 platform will enable the discovery and development of drug candidates targeting cancer, infectious and autoimmune diseases, leveraging its unique scalability Autoimmune diseases represent a high unmet medical need and offer significant partnership potential across all stages of drug development Evaxion also announces additional 2026 company milestones and maintains cash runway into second half of 2027 COPENHAGEN, Denmark, January 13, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, will expand the use of its proprietary AI-Immunology\u2122 platform to also discover and develop new treatments for autoimmune diseases. Thus, Evaxion will in the &hellip; Continue reading &quot;Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T13:57:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE1OTA0MSM0MDIzMTU2NzgjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases\",\"datePublished\":\"2026-01-13T13:57:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/\"},\"wordCount\":829,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE1OTA0MSM0MDIzMTU2NzgjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/\",\"name\":\"Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE1OTA0MSM0MDIzMTU2NzgjMjI1MjA4Nw==\",\"datePublished\":\"2026-01-13T13:57:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE1OTA0MSM0MDIzMTU2NzgjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE1OTA0MSM0MDIzMTU2NzgjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases - Market Newsdesk","og_description":"Evaxion adds autoimmune disease as a third disease area as it expands its therapeutic focus In future, Evaxion\u2019s proprietary AI-Immunology\u2122 platform will enable the discovery and development of drug candidates targeting cancer, infectious and autoimmune diseases, leveraging its unique scalability Autoimmune diseases represent a high unmet medical need and offer significant partnership potential across all stages of drug development Evaxion also announces additional 2026 company milestones and maintains cash runway into second half of 2027 COPENHAGEN, Denmark, January 13, 2026 &#8211; Evaxion A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, will expand the use of its proprietary AI-Immunology\u2122 platform to also discover and develop new treatments for autoimmune diseases. Thus, Evaxion will in the &hellip; Continue reading \"Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-13T13:57:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE1OTA0MSM0MDIzMTU2NzgjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases","datePublished":"2026-01-13T13:57:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/"},"wordCount":829,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE1OTA0MSM0MDIzMTU2NzgjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/","name":"Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE1OTA0MSM0MDIzMTU2NzgjMjI1MjA4Nw==","datePublished":"2026-01-13T13:57:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE1OTA0MSM0MDIzMTU2NzgjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE1OTA0MSM0MDIzMTU2NzgjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-ai-immunology-platform-into-autoimmune-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion expands AI-Immunology\u2122 platform into autoimmune diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=926760"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926760\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=926760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=926760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=926760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}